Trial Details

TERMINATED
Basic Information
Clinical ID c2459
Identifier NCT03462966
Trial Title Rifaximin on Visceral Hypersensitivity
Trial URL Visit Original Page
Study Information
Study Results

YES

Conditions Visceral Hypersensitivity|Irritable Bowel Syndrome
Interventions DRUG: Rifaximin
Participant Information
Sponsor Cedars-Sinai Medical Center
City Los Angeles
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE2
Time Information
Start Date 2018-07-01
Primary Completion Date 2021-11-19
Completion Date 2021-11-19